Program for IWWM 12
- Welcome Reception
- Day 1 - Thursday, October 17
- Day 2 - Friday, October 18
- Day 3 - Saturday, October 19
- Download Program and Abstracts
Wednesday, October 16, 2024
16:00 - 18:00 Early Registration
18:00 - 20:00 Welcome Reception
Conference Facilities at the Prague Marriott
Thursday, October 17, 2024
[7:45-8:00] Welcome to IWWM-12
Christian Buske, Jeffrey Matous, and Steven Treon [Workshop Organizers]
[8:00-9:00] Session I
WM Predisposition
Romanos Sklavenitis-Pistofidis, Gareth Morgan [Chairs]
Findings from the iSTOP Study
Sigurdur Kristinsson, Landspitali-The National University Hospital of Iceland, Iceland
Large scale GWAS illuminates disease aetiology for WM and LPL
Sonja Berndt, National Institutes of Health, USA
Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in WM Compared to IgM-MGUS
Stephen Ansell, Mayo Clinic, United States
Multi-Omics for Deciphering Mechanisms of Progression in Pre-Malignant IgM Gammopathies
Simone Ferrero, Università di Torino/Ematologia Universitaria, Italy
[8:45] Panel Discussion, All Session I Speakers
[9:00-10:00] Session II
WM/LPL Genomics I
Bruno Paiva, Christopher Oakes [Chairs]
Using Mutographs to Define the Molecular Landscape and Cell of Origin of WM
Gareth Morgan, N.Y.U. Grossman School of Medicine, United States
Aberrant Expression of Spliced WNK2 Is an Early event in MYD88-Mutated WM that Activates ERK 1/2
and supports Tumor Growth
Maria Luisa Guerrera, Dana Farber Cancer Institute, United States
Molecular Clusters and Tumor-immune Drivers of IgM Monoclonal Gammopathies
Patrizia Mondello, Mayo Clinic, United States
Clonal Architecture and Evolutionary History of WM at the Single-cell Level
Cristina Jiménez, Hospital Universitario de Salamanca, Spain
Chromatin Accessibility Landscape and Regulatory Networks of IgM monoclonal Gammopathies
David Moreno, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
[9:50] Panel Discussion, All Session II Speakers
[10:00-10:30] Mid-Morning Break & Networking
[10:30-11:30] Session III
WM/LPL Genomics II
Nikhil Munshi, Marzia Varettoni [Chairs]
Harnessing Epigenetic Signatures for Classification of WM
Christopher Oakes, Ohio State University, James Comprehensive Cancer Center, United States
Landscape of IgH Gene Repertoire and Clinical Relevance to LPL/WM
Mu Hao, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital, China
Single Cell multi-omics for minimally invasive assessment of Treatment efficacy in WM
Bruno Paiva, Clinica Universidad de Navarra, Spain
Clonal Hematopoiesis in Patients with WM
Adam Sperling, Dana Farber Cancer Institute, United States
[11:15] Panel Discussion, All Session III Speakers
[11:30-12:30] Session IV
Single Cell RNA Analysis
Irene Ghobrial/Bruno Paiva [Chairs]
Single-Cell RNA Analysis of Tumor and Immune Cells in Asymptomatic WM
Romanos Sklavenitis-Pistofidis, Harvard Medical School, Broad Institute of MIT & Harvard , United States
Single-Cell RNA Analysis of MYD88 Mutated and Wild-type WM
Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece
Single-Cell RNA reveals Stem Cell like Subsets in WM Progression
Xinxin Cao, Peking Union Medical College Hospital, China
Single-Cell RNA reveals Tumor Heterogeneity and Immunosuppressive Microenvironment in WM
Hao Sun, Dana Farber Cancer Institute, United States
[12:15] Panel Discussion, All Session IV Speakers
[12:30-13:30] LUNCH
[13:30-14:30] Session V
Keynote Lectures
Sub-typing WM by Multi-Omic Analysis
Keynote Moderator: Christian Buske
Keynote Speaker: Zachary Hunter, Dana Farber Cancer Institute, United States
[13:50] Topic Discussion
BM Stromal Cells and Transcriptional Regulation: Lessons for WM
Keynote Moderator: Christian Buske
Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, United States
[14:20] Topic Discussion
[14:30-15:15] Session VI
Molecular Diagnostics in WM
Ramón García Sanz/Roman Hajek [Chairs]
Clinical Implications of Genomic Profiling
Carlos Fernandez de Larrea Rodríguez, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
Digital Droplet (ddPCR) for Detection of MYD88 L265P Variants
Daniela Drandi, Università di Torino/Ematologia Universitaria, Italy
Molecular Remissions is an Independent Predictor of Progression-Free Survival in WM
Marzia Varettoni, Fondazione IRCCS Policlinico San Matteo, Italy
[15:00] Panel Discussion, All Session VI Speakers
[15:15-15:45] Mid-Afternoon Break & Networking
[15:45-16:30] Session: VII
Keynote Lecture
MYD88 and CXCR4 Signaling Cascades
Keynote Moderator: Adrian Wiestner, NHLBI, NIH, Hematology Branch, United States
Keynote Speaker: Steven Treon, Dana Farber Cancer Institute, United States
[16:15] Topic Discussion
[16:30-17:45] Session: VIII
Plenary Session I
Gareth Morgan, Zachary Hunter [Chairs]
Genomic Landscape of IgM MGUS and Stable vs. Progressive Asymptomatic WM Patients
Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece
Single Cell Multi-omics for Phenotypic Characterization of Clonal B Cells in Patients with IGM MGUS and WM
Carmen González Díaz-Cano, Universidad de Navarra, Spain
Characterization of WM/LPL using Single Cell Transcriptomic Analysis
Minghao Dang, MD Anderson Cancer Center, United States
A Multi-omic Analysis of WM Defines Three Subtypes of Disease
Dylan Gagler, Perlmutter Cancer Center, NYU Langone Health, United States
Determining the Mutational Landscape of WM by Liquid Biopsy: Results of the ECWM-2 Trial
Philipp Nakov, Universitätsklinikum Schleswig-Holstein, Germany
[17:40] Panel Discussion, All Session VIII Speakers
[19:00] Opening Ceremonies and Awards Presentation
[18:15] Buses begin departing from the Hotel
- Keynote Speaker: BeiGene, Inc.
- Presentation of Jan Gosta Waldenstrom Awards
- Presentation of Robert A. Kyle Awards
Friday, October 18, 2024
[8:00-9:00] Session IX
Tumor Immune Microenvironment
Stephen Ansell & José Martínez Climent [Chairs]
Dysfunctions of Innate and Adaptive Immune Tumor Microenvironment in WM
Jana Jakubikova, Cancer Research Institute, Biomedical Research Center SAS, Slovakia
Deciphering the Immune Microenvironment in WM
Aldo Roccaro, ASST Spedali Civili di Brescia, Italy
Analysis of Molecular and Microenvironment Landscape and Its Role in Drug Resistance in WM
Damien Roos-Weil, Sorbonne University, Groupe hospitalier Pitié-Salpêtrière, France
The Characterization and Modeling of MYD88 L265P Mutation and Chromosome 6q Deletion in Murine B-Cells
Ruben Carrasco, Dana Farber Cancer Institute, United States
[8:45] Panel Discussion, All Session IX Speakers
[9:00-10:00] Session X
Chemoimmunotherapy in WM I
Shirley D’Sa & M.J. Kersten [Chairs]
Dexamethasone, Rituximab, and Cyclophosphamide (DRC) versus Bortezomib-DRC (B-DRC) in WM
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
Long-term Outcomes of FILO Study: Frontline Benda-Rituximab in WM
Veronique Leblond, Hôpital Pitié Salpêtrière,France
Multicenter Observational Study of Benda-Rituximab vs. RCD
Francesco Autore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy
Long-term Outcomes of 678 patients with Symptomatic WM
Elham Askari, Hospital Universitario Fundación Jiménez Díaz, Spain
[9:45] Panel Discussion, All Session X Speakers
[10:00-10:30] Mid-Morning Break & Networking
[10:30-11:30] Session XI
Chemoimmunotherapy in WM II
Veronique Leblond & Meletios Dimopoulos [Chairs]
Role of Proteasome Inhibitors in WM
M.J. Kersten, University of Amsterdam, The Netherlands
Management of Transformed WM
Eric Durot, Hopital Robert Debre, Hematologie Clinique, France
Final Analysis of Innovative Study; Ibrutinib Rituximab vs. Placebo/Rituximab: Clinical and Genomic Findings
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
Comparative Outcomes of Benda-R vs. Ibrutinib in Frontline WM
Jithma Abeykoon, Mayo Clinic, United States
[11:15] Panel Discussion, All Session XI Speakers
[11:30-12:30] Session XII
BTK-Inhibitors in WM I
Stathis Kastritis & Marek Trneny [Chairs]
Long Term Findings of ASPEN Study: Clinical Outcomes
Meletios Dimopoulos, University of Athens School of Medicine, Greece
Long Term Updates on Ibrutinib and Venetoclax in Frontline WM
Jorge Castillo, Dana Farber Cancer Institute, United States
ECWM-2 Prospective Study
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
BRAWM Study: Bendamustine, Rituximab and Acalabrutinib in Frontline WM
Neil Berinstein, Odette Cancer Center, Canada
[12:15] Panel Discussion, All Session XII Speakers
[12:30-13:30] IWWM12 LUNCH
Moravia Hall
[12:30-13:30] Young Investigator Mentoring LUNCH
Studio G
[13:30-14:30] Session: XIII
BTK-Inhibitors in WM II
Alessandra Tedeschi & Ranjana Advani [Chairs]
Pirtobrutinib in Relapsed/Refractory WM: Results from Bruin Study
- Lia Palomba, Memorial Sloan-Kettering Cancer Center, United States
Tirabrutinib in Symptomatic WM and Bing-Neel Syndrome (BNS)
Naohiro Sekiguchi, National Hospital Organization Disaster Medical Center ,Japan
Orelabrutinib in Relapsed/Refractory WM: Long-Term Follow-up
Xinxin Cao, Peking Union Medical College Hospital, China
Prospective Study of Acalabrutinib and Rituximab in Symptomatic Anti-MAG mediated IgM Peripheral Neuropathy
Shayna Sarosiek, Dana Farber Cancer Institute, United States
[14:15] Panel Discussion, All Session XIII Speakers
[14:30-15:00] Session XIV
Keynote Lecture
Utility of MRD in Clinical Care and New Drug Development in Myeloma
Keynote Moderator: Steven Treon, Dana Farber Cancer Institute, United States
Keynote Speaker: Kenneth Anderson, Dana Farber Cancer Institute, United States
[14:50] Topic Discussion
[15:00-16:00] Session: XV
BTK-I Intolerant and Resistant Disease
Carlos Fernández de Larrea Rodríguez & Prashant Kapoor [Chairs]
Dose reduction following ibrutinib intolerance in WM patients
Shayna Sarosiek, Dana Farber Cancer Institute, United States
Zanubrutinib for Patients intolerant of other BTK-I
Mazyar Shadman, Fred Hutchinson Cancer Research Center, United States
Bortezomib for Patients Failing BTK-I
Jahanzaib Khwaja, University College London Hospitals, United Kingdom
BGB-16673 BTK Degrader
John Seymour, Peter MacCallum Cancer Centre, Australia
[15:45] Panel Discussion, All Session XV Speakers
[16:00-17:00] Session XVI
Keynote Lectures
Genomic Evolution and Resistance Following BTK-Inhibitors in CLL:
Lessons for Sequencing and Managing BTK-Inhibitors
Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, United States
Keynote Speaker: Jennifer Brown, Dana Farber Cancer Institute, United States
[16:20] Topic Discussion
Role of BTK Inhibitors as Facilitators of Cellular Immunotherapies
Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, United States
Keynote Speaker: Adrian Wiestner, NHLBI, NIH, Hematology Branch, United States
[16:50] Topic Discussion
[17:00-19:00] Session XVII
IWWM12 Poster Highlights
Andrew Branagan & Josephine Vos [Chairs]
Poster Session & Reception
Moravia Hall
[19:30] Faculty Dinner Reception
[19:00] Departure in the Hotel Lobby
Saturday, October 19, 2024
[8:00-9:00] Session XVIII
Special Topics Lectures
Moshe Gat & Claudio Cerchione [Chairs]
Management of IgM De-Myelinating neuropathy
Speaker: Shirley D’Sa, UC London Hospitals NHS, United Kingdom
Management of Bing Neel Syndrome
Speaker: Monique Minnema, University of Utrecht, The Netherlands
Diagnostic Workup and Management of WM-related Amyloid
Speaker: Giampaolo Merlini, University of Pavia, Italy
Diagnostic Workup and Management of Monoclonal IgM-related Cold Agglutinin Disease
Speaker: Josephine Vos, University of Amsterdam, The Netherlands
[8:45] Panel Discussion, All Session XVIII Speakers
[9:00-10:00] Session: XIX
Plenary Session II
Ranjana Advani & Meletios Dimopoulos [Chairs]
Phase I Study of the Novel BCL2 Inhibitor Sonrotoclax in Relapsed/Refractory WM
Ramón García Sanz, University Hospital Gregorio Marañón, Spain
Zanubrutinib in Bing Neel Syndrome: Efficacy and Tolerability
Anne-Marie Becking, Amsterdam UMC, The Netherlands
Real World Outcomes of ASCT in Patients with WM: Report from LWP EBMT
Charalampia Kyriakou, University College London Hospitals NHS Trust, United Kingdom
Novel BiFunctional HCK/BTK Protacs for MYD88 Mutated WM and ABC DLBCL
John M. Hatcher, Dana Farber Cancer Institute, United States
[9:45] Panel Discussion, All Session XIX Speakers
[10:00-10:30] Mid-Morning Break & Networking
[10:30-12:30] Session XX
Great Debates in WM
Eva Kimby & Irene Ghobrial [Chairs]
[10:30-11:00] Great Debate I
What should be the Standard for Frontline Treatment for WM?
For Bendamustine plus Rituximab
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. of Internal Medicine III, Germany
For Cyclophosphamide, Dexamethasone, Rituximab (CDR)
Stathis Kastritis, National and Kapodistrian University of Athens, Greece
For BTK-inhibitors
Alessandra Tedeschi, A. O. Ospedale Niguarda Ca' Granda, Italy
[11:00-11:30] Great Debate II
What is the optimal approach for frontline use of BTK-inhibitors in WM?
For Limited Duration Combination Therapy with BTK-inhibitors in WM
Neil Berinstein, Odette Cancer Center, Canada
For Continuous Administration of BTK-inhibitors as Monotherapy
Prashant Kapoor, Mayo Clinic, United States
[11:30-12:00] Great Debate III
What is the next best treatment for WM patients progressing on covalent BTK-inhibitors?
For Pirtobrutinib
- Lia Palomba, Memorial Sloan Kettering Cancer Center, United States
For Venetoclax
Jorge Castillo, Dana Farber Cancer Institute, United States
[12:00-12:30] Great Debate IV
Should TP53 Alterations be Considered for Treatment Decision Making in WM Patients?
Yes, TP53 Alterations should be considered
Ramón García Sanz, University Hospital Gregorio Marañón, Spain
No, TP53 Alterations should not considered
Shirley D’Sa, University College London Hospitals NHS Trust, United Kingdom
[12:30-13:30] LUNCH
[13:30-14:30] Session XXI
Novel Drug Development for WM
Ramón García Sanz & Lu-Gui Qiu [Chairs]
Development of IRAK1/IRAK4 Bifunctional PROTACs (Proteolysis-Targeting Chimeras) for MYD88 mutated WM
Sara Buhrlage, Dana Farber Cancer Institute, United States
Pacritinib is a Highly Potent Inhibitor of HCK and IRAK and Triggers High Levels of Apoptosis in WM
Shirong Liu, Dana Farber Cancer Institute, United States
Pre-clinical Models for Prediction of Immunotherapy Outcomes and Immune Evasion
Jose Martínez Climent, University of Navarra, Spain
Development of BTK/BTK -IKZF Protacs for B-Cell Malignancies
Paula O’Connor, Nurix Therapeutics, Inc., United States
[14:15] Panel Discussion, All Session XXI Speakers
[14:30-15:30] Session XXII
Clinical Trials in Progress for WM I
Jeffrey Matous & Shayna Sarosiek [Chairs]
Carfilzomib With and Without Ibrutinib in Frontline and Relapsed/Refractory WM (CZAR-1)
Meletios Dimopoulos, University of Athens School of Medicine, Greece
Rainbow Trial: Ibrutinib Rituximab vs. DRC in Newly Diagnosed WM
Rebecca Auer, Barts Health NHS Trust, United Kingdom
Zanubrutinib plus Benda-R in Newly diagnosed WM
Shuhua Yi, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), China
Pirtobrutinib and Venetoclax in Relapsed or Refractory WM
Jorge Castillo, Dana Farber Cancer Institute, United States
[15:15] Panel Discussion, All Session XXII Speakers
[15:30-16:00] Mid-Afternoon Break & Networking
[16:00-17:00] Session XXIII
Clinical Trials in Progress for WM II
Efstathios Kastritis & Prashant Kapoor [Chairs]
Loncastuxumab in Relapsed/Refractory WM
Shayna Sarosiek, Dana Farber Cancer Institute, United States
Sonrotoclax for Relapsed/Refractory WM
Jeffrey Matous, Colorado Blood Cancer Institute, United States
Multi-center Trial of iopofosine I 131 in Relapsed/Refractory WM
Andrei Shustov, Cellectar Biosciences, United States
CD20-Directed CAR-T Cell
Mazyar Shadman, Fred Hutchinson Cancer Res Center, United States
[16:45] Panel Discussion, All Session XXIII Speakers
[17:00-18:00] Session XXIV
Clinical Trials in Progress for WM III
Roger Owen & Pierre Morel [Chairs]
WM-NET Clinical Trial Priorities
Jorge Castillo, Dana Farber Cancer Institute, United States
Gottfried von Keudell, Beth Israel Deaconess Medical Center, United States
ECWM Clinical Trial Priorities
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
[19:00] Dinner Reception and Closing Ceremonies
[18:15] Buses begin departing from the Hotel
- Presentation of Peter S. Bing Humanitarian Awards
- Presentation of the Young Investigator Awards
- Announcement and Welcome to IWWM-13